Signal transduction

HUTCHMED Initiates Phase II Registration Study of HMPL-689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China

Retrieved on: 
星期四, 四月 29, 2021
Branches of biology, Tyrosine kinases, B-cell receptor, Tyrosine-protein kinase SYK, LYN, Clinical endpoint, Progression-free survival, Signal transduction

The primary endpoint is objective response rate (\xe2\x80\x9cORR\xe2\x80\x9d), with secondary endpoints including complete response rate (CRR), progression-free survival (PFS), time to response (TTR) and duration of response (DoR).

Key Points: 
  • The primary endpoint is objective response rate (\xe2\x80\x9cORR\xe2\x80\x9d), with secondary endpoints including complete response rate (CRR), progression-free survival (PFS), time to response (TTR) and duration of response (DoR).
  • The trial is being conducted in over 35 sites in China.
  • Upon an antigen binding to B-cell receptors, PI3K\xce\xb4 can be activated through the Lyn and Syk signaling cascade.
  • For further discussion of these and other risks, see HUTCHMED\xe2\x80\x99s filings with the U.S. Securities and Exchange Commission and on AIM.

Poxel Announces its Participation at the Mitochondria-Targeted Drug Development Summit

Retrieved on: 
星期四, 四月 29, 2021
Health, Diabetes, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Signal transduction, Chronic condition, Medical terminology, MTOR, Biology

Our platforms also represent differentiated approaches which offer the potential for additive or synergistic efficacy when used in combination with other mechanisms.

Key Points: 
  • Our platforms also represent differentiated approaches which offer the potential for additive or synergistic efficacy when used in combination with other mechanisms.
  • In its mid-to-late-stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities.
  • Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases.
  • Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

Retrieved on: 
星期四, 四月 29, 2021
Branches of biology, Growth factors, Vascular endothelial growth factor, Angiology, Tyrosine kinase receptors, Signal transduction

As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.

Key Points: 
  • As the world\'s first bispecific fusion protein targeting VEGF and complement, IBI302 can simultaneously inhibit the proliferation of VEGF-mediated signaling pathway and reduce the inflammatory response mediated by complement activation.
  • The overall safety profile is similar to that of marketed single-target anti-VEGF drugs.
  • IBI302 was designed to provide more targeted treatment and interventions to the cause of nAMD by adding additional targets.
  • The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.

X4 Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 6, 2021

Retrieved on: 
星期四, 四月 22, 2021
Branches of biology, Chemokine receptors, Signal transduction, CXCR4, CXC chemokine receptors, XC2, Chemokine, Receptor antagonist

The conference call can be accessed by dialing (866) 721-7655 from\xc2\xa0the United States\xc2\xa0or (409) 216-0009 internationally, followed by the conference ID: 5658628.

Key Points: 
  • The conference call can be accessed by dialing (866) 721-7655 from\xc2\xa0the United States\xc2\xa0or (409) 216-0009 internationally, followed by the conference ID: 5658628.
  • The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals\xe2\x80\x99 website at www.x4pharma.com .
  • The company\xe2\x80\x99s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy.
  • X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer.

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

Retrieved on: 
星期三, 四月 21, 2021
Branches of biology, Protein complexes, Biology, Signal transduction, mTORC1, MTOR

The trial is an open-label dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of RMC-5552 in patients with advanced relapsed/refractory solid tumors.

Key Points: 
  • The trial is an open-label dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics of RMC-5552 in patients with advanced relapsed/refractory solid tumors.
  • The compound is designed to inhibit mTORC1 and preserve the natural tumor suppressive activity of 4EBP1, without the undesired inhibition of mTORC2.
  • Selective inhibition of mTORC1 to reactivate 4EBP1 is a potential therapeutic strategy for patients with tumors bearing such mutations.
  • Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.\n'

StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells

Retrieved on: 
星期三, 四月 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Biology, Signal transduction, Stem cells, Cell signaling, Evolutionary developmental biology, Cancer stem cell, Carcinogenesis, Notch signaling pathway, Hedgehog signaling pathway, Sonic hedgehog, Epithelial–mesenchymal transition

StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.

Key Points: 
  • StemSynergy Therapeutics, Inc., who collaborated on this study holds worldwide exclusivity to develop these molecules for the clinic.\n"The Notch pathway is an extremely attractive target for cancer therapeutics, as it is a critical driver of many human cancers.
  • "Specifically, NADI-351 clears cancer stem cells by starving them of Notch signaling and causes cell death in tumors, including esophageal and triple-negative breast cancer.
  • At the same time this breakthrough science is being published, StemSynergy Therapeutics is developing this class of compound for clinical evaluation.
  • Our mission is to optimize efficacy against the pathways required to drive cancer stem cells, such as the Wnt, Sonic Hedgehog and Notch signaling pathways.

Worldwide Functional Proteins Industry to 2027 - Growth in Consumption of Functional Food is Driving the Market - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 9, 2021
Retail, Health, Food, Beverage, Other Health, Signal transduction, Proteomics, Biotechnology, Molecular biology

The report highlights key factors driving the market growth and prominent players along with their developments in the market.

Key Points: 
  • The report highlights key factors driving the market growth and prominent players along with their developments in the market.
  • The awareness among consumers regarding the benefits offered by functional proteins is contributing significantly to the growth of the functional proteins market.
  • Functional proteins are a complex mixture of biologically active proteins that supports and maintains normal immune function.
  • Features key findings and crucial progressive industry trends in the global functional proteins market, thereby allowing players to develop effective long-term strategies.

BioTheryX Announces Expansion of Scientific Advisory Board

Retrieved on: 
星期三, 四月 7, 2021
Branches of biology, Biology, Signal transduction, Cell biology, Evolutionary developmental biology, Genes, Wnt signaling pathway, NF-κB, Cell signaling, Kevan Shokat

SAN DIEGO, April 7, 2021 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D.

Key Points: 
  • SAN DIEGO, April 7, 2021 /PRNewswire/ --BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today announced the expansion of its Scientific Advisory Board (SAB) with the appointment of three new members: David Komander, Ph.D., Kevan M. Shokat, Ph.D. and Peter Walter, Ph.D.
  • His research work focuses on signaling pathways regulating innate immunity and inflammation, particularly in the context of cancer.
  • His lab deciphered key steps in the activation of the NFkB and Wnt signaling pathways and studied them in animal models of cancer.
  • This technology is designed to utilize the body's own protein disposal system to selectively degrade and remove disease-causing proteins.

Can-Fite: Cannabis Compound Inhibits Liver Cancer Growth in Preclinical Studies

Retrieved on: 
星期一, 四月 5, 2021
Oncology, Alternative medicine, Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Biology, Signal transduction, Liver, Organs, Wnt signaling pathway, Medical cannabis, Cancer

(NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today it has completed pre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth.

Key Points: 
  • (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today it has completed pre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth.
  • The Wnt signaling pathway is known to be highly active in controlling the growth of liver cancer cells.
  • These findings present a novel therapeutic opportunity for cannabis derived compounds in liver cancer and further enhance Can-Fites assets.
  • Liver cancer is one of the leading causes of cancer deaths globally, with an estimated 854,000 new cases and 810,000 deaths annually.

Alternative Protein Market to be worth $27.05 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis and Forecasts by Meticulous Research®

Retrieved on: 
星期三, 三月 31, 2021
Nutrition, Protein, Branches of biology, Proteomics, Life sciences, Biotechnology, Biology, Omics, Signal transduction

A major shift in the global market's consumer behavior is increasing interest in alternative protein sources from plant-based to insects.

Key Points: 
  • A major shift in the global market's consumer behavior is increasing interest in alternative protein sources from plant-based to insects.
  • Key Findings in the Global Alternative Proteins Market Study:
    Based on stage/type, the alternative protein market is segmented into emerging alternative proteins, adolescent alternative proteins, and matured alternative proteins.
  • In 2020, the matured alternative proteins segment accounted for the largest share of the overall alternative protein market.
  • Quick Buy Alternative Protein Market Research Report: https://www.meticulousresearch.com/Checkout/34883398
    Based on application, the alternative proteins market is segmented into plant protein-based products, insect protein-based products, and microbial protein-based products.